Acadia Pharmaceuticals (ACAD) Receivables - Net (2016 - 2026)

Acadia Pharmaceuticals' Receivables - Net history runs 11 years deep, the most recent figure standing at $135.4 million for Q1 2026.

• On a quarterly basis, Receivables - Net rose 28.0% year-over-year to $135.4 million in Q1 2026; TTM through Mar 2026 was $135.4 million, a 28.0% increase from a year earlier, with the FY2025 full-year figure at $121.5 million, up 23.01% from the prior year.
• Receivables - Net advanced to $135.4 million in Q1 2026 per ACAD's latest filing, from $121.5 million in the prior quarter.
• Across five years, Receivables - Net topped out at $135.4 million in Q1 2026 and bottomed at $55.7 million in Q3 2022.
• The 5-year median for Receivables - Net is $98.2 million (2024), against an average of $92.3 million.
• Across the five-year window, Receivables - Net decreased 8.18% in 2022 and jumped 66.51% in 2023, its largest moves.
• Year by year, Receivables - Net stood at $62.2 million in 2022, then soared by 58.0% to $98.3 million in 2023, then grew by 0.48% to $98.7 million in 2024, then grew by 23.01% to $121.5 million in 2025, then advanced by 11.44% to $135.4 million in 2026.
• Per Business Quant, the three latest ACAD Receivables - Net figures stand at $135.4 million (Q1 2026), $121.5 million (Q4 2025), and $115.8 million (Q3 2025).